122 related articles for article (PubMed ID: 20508521)
1. Apolipoprotein B synthesis inhibition: results from clinical trials.
Visser ME; Kastelein JJ; Stroes ES
Curr Opin Lipidol; 2010 Aug; 21(4):319-23. PubMed ID: 20508521
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
3. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
Ricotta DN; Frishman W
Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.
Akdim F; Stroes ES; Sijbrands EJ; Tribble DL; Trip MD; Jukema JW; Flaim JD; Su J; Yu R; Baker BF; Wedel MK; Kastelein JJ
J Am Coll Cardiol; 2010 Apr; 55(15):1611-8. PubMed ID: 20378080
[TBL] [Abstract][Full Text] [Related]
5. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA; Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
[TBL] [Abstract][Full Text] [Related]
6. Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Patel N; Hegele RA
Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601
[TBL] [Abstract][Full Text] [Related]
7. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
[TBL] [Abstract][Full Text] [Related]
8. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
Toth PP
J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
[TBL] [Abstract][Full Text] [Related]
9. Antisense apolipoprotein B therapy: where do we stand?
Akdim F; Stroes ES; Kastelein JJ
Curr Opin Lipidol; 2007 Aug; 18(4):397-400. PubMed ID: 17620855
[TBL] [Abstract][Full Text] [Related]
10. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
[TBL] [Abstract][Full Text] [Related]
11. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia.
Haddley K
Drugs Today (Barc); 2011 Dec; 47(12):891-901. PubMed ID: 22348914
[TBL] [Abstract][Full Text] [Related]
12. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
Gelsinger C; Steinhagen-Thiessen E; Kassner U
Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
[TBL] [Abstract][Full Text] [Related]
14. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.
Visser ME; Akdim F; Tribble DL; Nederveen AJ; Kwoh TJ; Kastelein JJ; Trip MD; Stroes ES
J Lipid Res; 2010 May; 51(5):1057-62. PubMed ID: 20008831
[TBL] [Abstract][Full Text] [Related]
15. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
Ito MK
Ann Pharmacother; 2007 Oct; 41(10):1669-78. PubMed ID: 17848425
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials.
Panta R; Dahal K; Kunwar S
J Clin Lipidol; 2015; 9(2):217-25. PubMed ID: 25911078
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM
Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603
[TBL] [Abstract][Full Text] [Related]
18. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein B antisense inhibition--update on mipomersen.
Gebhard C; Huard G; Kritikou EA; Tardif JC
Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
[TBL] [Abstract][Full Text] [Related]
20. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials.
Li N; Li Q; Tian XQ; Qian HY; Yang YJ
Am J Cardiovasc Drugs; 2014 Oct; 14(5):367-76. PubMed ID: 25027352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
